Identification of Very Red Counterparts of SiO Maser and OH/IR Objects in the GLIMPSE Survey

Using the 3.6/4.5/5.8/8.0 micron images with 1.2 arcsec pixel resolution from the Spitzer/GLIMPSE survey, we investigated 23 masing and 18 very red objects that were not identified in the 2MASS survey. Counterparts for all selected objects were found in the GLIMPSE images. Color indices in these IR bands suggest the presence of a high-extinction layer of more than a few tenths of a solar mass in front of the central star. Furthermore, radio observations in the SiO and H2O maser lines found characteristic maser-line spectra of the embedded objects, e.g., the SiO J=1-0 line intensity in the v=2 state stronger than that of the v=1 state, or very widespread H2O maser emission spectra. This indicates that these objects are actually enshrouded by very thick circumstellar matter, some of which cannot be ascribed to the AGB wind of the central star. Individually interesting objects are discussed, including two newly found water fountains and an SiO source with nebulosity.Comment: High resolution figures available at ftp://ftp.nro.nao.ac.jp/nroreport/no653.pdf.gz. ApJ No. 655 no.1 issue in pres

Observatory of Strategic Developments Impacting Urban Logistics (2017 version)

Urban freight living labs need to operate in full recognition of the challenges that will shape the mobility of goods in urban areas in the future. These challenges are several: macroeconomic, micro-economic, demographic, technological, societal, and legal. To help CITYLAB cities implement their urban freight initiatives, a better understanding of These challenges is necessary. This is what this Observatory of strategic developments impacting urban logistics intends to do, by providing data and analysis on some of the most important, or less well known, trends that will shape the urban mobility of goods in the future. This second version (2017) of the Observatory provides data and analyses on 1) Logistics Sprawl; 2) E-commerce; and 3) Service trips. Our findings about the main impacts of these three trends for cities involved in urban freight living labs are the following: - The number of logistics facilities (in their diversity: warehouses, fulfilment centres, distribution centres, cross-dock terminals) is increasing in cities, especially cities of some logistics importance as large consumer markets and/or logistics hubs processing the flow of goods generated by the global economy. These facilities are generally located in suburban areas, but a new niche market of urban warehouses is emerging. - Both e-commerce and logistics sprawl generate a rise in freight vehicles in urban areas, dominated by small vehicles, while medium to large lorries are relatively less important. These vehicles performing delivery operations are visible in neighbourhoods and at times of day when they were not identified before: residential neighbourhoods, residential building blocks, side streets, in the early evening and on week-ends. Emerging new types of vehicles (clean delivery vehicles, two and three wheelers) are now visible in urban centres. - Innovations in the urban supply chains include diverse forms of pick-up points and click-and-collect solutions, while the recent but extremely rapid rise in Technologies and algorithms supporting instant deliveries (on-demand deliveries within less than two hours) brings with it a flourish of new companies connecting customers, suppliers and independent couriers, often using bicycles. - The overall impact of these new trends on energy and carbon emission related to urban freight is difficult to assess. Urban freight in general, for the Paris region, brings the following environmental impact: the share of traffic-related CO2, NOx and PM10 due to urban freight is 2.5 times larger than the share of vans and trucks in the regional traffic. The contribution of urban freight to air pollution is larger in the city of Paris. Social costs of air pollution caused by road traffic in general amount to 0.9% of the regional GDP in 2012. Some of the new trends bring more CO2 emissions, such as the relocation of logistics facilities far away in the suburbs, as deconsolidated shipments are delivered to urban consumers and businesses in smaller and more numerous vans. Some trends bring less CO2 emissions, with a rise in cleaner vehicles and innovative solutions such as drop-off/pickup points or bikesupported instant deliveries. Substitution patterns between personal mobility and professional freight mobility can be a good, or a bad, thing for CO2 emissions, depending on the initial circumstances and the way personal shopping was done before online orders. - What is certain is that these changes bring diversity in the urban traffic flow. Instant couriers are using all sorts of transport modes, including foot, bicycles, electrically assisted cargocycles, motorbikes, and various types of vans and lorries. This can negatively impact traffic management, road safety and conflicts in road uses, congestion, air pollution. Also, the trends we have looked at bring new types of urban jobs, with many unresolved legal issues and poor working conditions in many instances. New types of logistics buildings bring architectural diversity and innovation in cities, but also complaints about noise, aesthetics, as well as congestion and pollution at entrance and exit points. - These environmental and social impacts have been so far poorly documented and researched. Consumers are the main drivers of the changes we have observed, but they are also the residents or visitors of urban areas, and for that they carry an important share of the burdens, as well as the benefits, of the new landscape of urban logistics. - Service trips are trips in commercial traffic induced by service oriented activities. According to the German study KiD 2010 service traffic accounts for 11.8% of traffic in terms of trips and for 19.9% in terms of kilometres travelled. There are differences in terms of vehicle types and economic sectors but few variations in Terms of spatial types. - An observatory on service traffic must take into account light duty vehicles and passenger cars in general. Establishment based analysis as well as vehicle based analysis can give detailed insight in traffic generation and traffic behaviour in Service traffic

A New Look at the Environmental Assessment of Logistics Sprawl Part 1: The Environmental Impact of Urban Road Freight: A Modeling Exercise for the Paris Region [Brief]

This research aims at improving knowledge on the environmental impacts of urban road freight (URF). It questions the gap between common beliefs about the environmental impact of URF and its specific empirical measurement

Microarray Analyses of Inflammation Response of Human Dermal Fibroblasts to Different Strains of Borrelia burgdorferi Sensu Stricto

In Lyme borreliosis, the skin is the key site of bacterial inoculation by the infected tick, and of cutaneous manifestations, erythema migrans and acrodermatitis chronica atrophicans. We explored the role of fibroblasts, the resident cells of the dermis, in the development of the disease. Using microarray experiments, we compared the inflammation of fibroblasts induced by three strains of Borrelia burgdorferi sensu stricto isolated from different environments and stages of Lyme disease: N40 (tick), Pbre (erythema migrans) and 1408 (acrodermatitis chronica atrophicans). The three strains exhibited a similar profile of inflammation with strong induction of chemokines (CXCL1 and IL-8) and IL-6 cytokine mainly involved in the chemoattraction of immune cells. Molecules such as TNF-alpha and NF-κB factors, metalloproteinases (MMP-1, -3 and -12) and superoxide dismutase (SOD2), also described in inflammatory and cellular events, were up-regulated. In addition, we showed that tick salivary gland extracts induce a cytotoxic effect on fibroblasts and that OspC, essential in the transmission of Borrelia to the vertebrate host, was not responsible for the secretion of inflammatory molecules by fibroblasts. Tick saliva components could facilitate the early transmission of the disease to the site of injury creating a feeding pit. Later in the development of the disease, Borrelia would intensively multiply in the skin and further disseminate to distant organs

European code against cancer 4th edition: 12 ways to reduce your cancer risk

This overview describes the principles of the 4th edition of the European Code against Cancer and provides an introduction to the 12 recommendations to reduce cancer risk. Among the 504.6 million inhabitants of the member states of the European Union (EU28), there are annually 2.64 million new cancer cases and 1.28 million deaths from cancer. It is estimated that this cancer burden could be reduced by up to one half if scientific knowledge on causes of cancer could be translated into successful prevention. The Code is a preventive tool aimed to reduce the cancer burden by informing people how to avoid or reduce carcinogenic exposures, adopt behaviours to reduce the cancer risk, or to participate in organised intervention programmes. The Code should also form a base to guide national health policies in cancer prevention. The 12 recommendations are: not smoking or using other tobacco products; avoiding second-hand smoke; being a healthy body weight; encouraging physical activity; having a healthy diet; limiting alcohol consumption, with not drinking alcohol being better for cancer prevention; avoiding too much exposure to ultraviolet radiation; avoiding cancer-causing agents at the workplace; reducing exposure to high levels of radon; encouraging breastfeeding; limiting the use of hormone replacement therapy; participating in organised vaccination programmes against hepatitis B for newborns and human papillomavirus for girls; and participating in organised screening programmes for bowel cancer, breast cancer, and cervical cancer

Association of the PHACTR1/EDN1 genetic locus with spontaneous coronary artery dissection

Background: Spontaneous coronary artery dissection (SCAD) is an increasingly recognized cause of acute coronary syndromes (ACS) afflicting predominantly younger to middle-aged women. Observational studies have reported a high prevalence of extracoronary vascular anomalies, especially fibromuscular dysplasia (FMD) and a low prevalence of coincidental cases of atherosclerosis. PHACTR1/EDN1 is a genetic risk locus for several vascular diseases, including FMD and coronary artery disease, with the putative causal noncoding variant at the rs9349379 locus acting as a potential enhancer for the endothelin-1 (EDN1) gene. Objectives: This study sought to test the association between the rs9349379 genotype and SCAD. Methods: Results from case control studies from France, United Kingdom, United States, and Australia were analyzed to test the association with SCAD risk, including age at first event, pregnancy-associated SCAD (P-SCAD), and recurrent SCAD. Results: The previously reported risk allele for FMD (rs9349379-A) was associated with a higher risk of SCAD in all studies. In a meta-analysis of 1,055 SCAD patients and 7,190 controls, the odds ratio (OR) was 1.67 (95% confidence interval [CI]: 1.50 to 1.86) per copy of rs9349379-A. In a subset of 491 SCAD patients, the OR estimate was found to be higher for the association with SCAD in patients without FMD (OR: 1.89; 95% CI: 1.53 to 2.33) than in SCAD cases with FMD (OR: 1.60; 95% CI: 1.28 to 1.99). There was no effect of genotype on age at first event, P-SCAD, or recurrence. Conclusions: The first genetic risk factor for SCAD was identified in the largest study conducted to date for this condition. This genetic link may contribute to the clinical overlap between SCAD and FMD

Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products – a PEARRL review.

Objectives: In this review, the current biopharmaceutical approaches for evaluation of oral formulation performance in paediatrics are discussed. Key findings: The paediatric gastrointestinal (GI) tract undergoes numerous morphological and physiological changes throughout its development and growth. Some physiological parameters are yet to be investigated, limiting the use of the existing in vitro biopharmaceutical tools to predict the in vivo performance of paediatric formulations. Meals and frequencies of their administration evolve during childhood and affect oral drug absorption. Furthermore, the establishment of a paediatric Biopharmaceutics Classification System (pBCS), based on the adult Biopharmaceutics Classification System (BCS), requires criteria adjustments. The usefulness of computational simulation and modeling for extrapolation of adult data to paediatrics has been confirmed as a tool for predicting drug formulation performance. Despite the great number of successful physiologically based pharmacokinetic models to simulate drug disposition, the simulation of drug absorption from the GI tract is a complicating issue in paediatric populations. Summary: The biopharmaceutics tools for investigation of oral drug absorption in paediatrics need further development, refinement and validation. A combination of in vitro and in silico methods could compensate for the uncertainties accompanying each method on its own

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

Publisher Copyright: © 2021 The Authors, some rights reserved.Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/ml; in plasma diluted 1:10) of IFN-alpha and/or IFN-omega are found in about 10% of patients with critical COVID-19 (coronavirus disease 2019) pneumonia but not in individuals with asymptomatic infections. We detect auto-Abs neutralizing 100-fold lower, more physiological, concentrations of IFN-alpha and/or IFN-omega (100 pg/ml; in 1:10 dilutions of plasma) in 13.6% of 3595 patients with critical COVID-19, including 21% of 374 patients >80 years, and 6.5% of 522 patients with severe COVID-19. These antibodies are also detected in 18% of the 1124 deceased patients (aged 20 days to 99 years; mean: 70 years). Moreover, another 1.3% of patients with critical COVID-19 and 0.9% of the deceased patients have auto-Abs neutralizing high concentrations of IFN-beta. We also show, in a sample of 34,159 uninfected individuals from the general population, that auto-Abs neutralizing high concentrations of IFN-alpha and/or IFN-omega are present in 0.18% of individuals between 18 and 69 years, 1.1% between 70 and 79 years, and 3.4% >80 years. Moreover, the proportion of individuals carrying auto-Abs neutralizing lower concentrations is greater in a subsample of 10,778 uninfected individuals: 1% of individuals 80 years. By contrast, auto-Abs neutralizing IFN-beta do not become more frequent with age. Auto-Abs neutralizing type I IFNs predate SARS-CoV-2 infection and sharply increase in prevalence after the age of 70 years. They account for about 20% of both critical COVID-19 cases in the over 80s and total fatal COVID-19 cases.Peer reviewe

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo